Association between the timing of maternal vaccination and newborns' anti-pertussis toxin antibody levels.
Adult
Antibodies, Bacterial
/ blood
Cross-Sectional Studies
Enzyme-Linked Immunosorbent Assay
Female
Fetal Blood
/ immunology
Humans
Immunity, Maternally-Acquired
/ immunology
Immunoglobulin G
/ metabolism
Infant
Infant, Newborn
Pertussis Toxin
/ immunology
Pregnancy
Pregnancy Trimester, Third
/ immunology
Vaccination
/ methods
Whooping Cough
/ immunology
Young Adult
Maternal antibodies
Maternal vaccination
Newborn infants
Pertussis
Tdap
Journal
Vaccine
ISSN: 1873-2518
Titre abrégé: Vaccine
Pays: Netherlands
ID NLM: 8406899
Informations de publication
Date de publication:
23 08 2019
23 08 2019
Historique:
received:
01
10
2018
revised:
03
04
2019
accepted:
25
04
2019
pubmed:
4
6
2019
medline:
22
9
2020
entrez:
3
6
2019
Statut:
ppublish
Résumé
Pertussis remains an important global public health concern, despite the presence of extensive immunization programs. Incidence and severity of pertussis are typically higher in neonates and young infants. As a strategy to protect these young infants, maternal vaccination with Tdap (tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis) has been recommended in Brazil. The objective of this study was to evaluate the effects of Tdap vaccination during pregnancy on the anti-pertussis toxin (PT) IgG response in mothers and their infants at birth. Maternal and cord blood samples were collected from vaccinated (n = 243) and unvaccinated (n = 75) pregnant women, at the time of delivery, from July 2015 to August 2016 in São Paulo, Brazil. Anti-PT IgG antibodies were quantified by Enzyme-Linked Immunosorbent Assay (ELISA) and geometric mean concentrations (GMC) were calculated. Relationship between timing of vaccination and antibody concentrations were evaluated. Maternal and cord blood GMCs among the vaccinated group were 5.4 and 5.6 fold higher [66.5 International Units (IU)/mL and 89.8 IU/mL] compared to the unvaccinated group (12.4 IU/mL and 16.1 IU/mL), respectively (p < 0.001). Higher anti-PT IgG GMCs were observed when vaccination occurred ≥60 days before delivery compared to <60 days, suggesting that vaccination early in the third trimester may be more effective than later in pregnancy. Tdap maternal vaccination results in significantly higher anti-PT IgG in newborn infants and supports the current recommendation of the Brazilian Immunization Program.
Sections du résumé
BACKGROUND
Pertussis remains an important global public health concern, despite the presence of extensive immunization programs. Incidence and severity of pertussis are typically higher in neonates and young infants. As a strategy to protect these young infants, maternal vaccination with Tdap (tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis) has been recommended in Brazil. The objective of this study was to evaluate the effects of Tdap vaccination during pregnancy on the anti-pertussis toxin (PT) IgG response in mothers and their infants at birth.
MATERIAL AND METHODS
Maternal and cord blood samples were collected from vaccinated (n = 243) and unvaccinated (n = 75) pregnant women, at the time of delivery, from July 2015 to August 2016 in São Paulo, Brazil. Anti-PT IgG antibodies were quantified by Enzyme-Linked Immunosorbent Assay (ELISA) and geometric mean concentrations (GMC) were calculated. Relationship between timing of vaccination and antibody concentrations were evaluated.
RESULTS
Maternal and cord blood GMCs among the vaccinated group were 5.4 and 5.6 fold higher [66.5 International Units (IU)/mL and 89.8 IU/mL] compared to the unvaccinated group (12.4 IU/mL and 16.1 IU/mL), respectively (p < 0.001). Higher anti-PT IgG GMCs were observed when vaccination occurred ≥60 days before delivery compared to <60 days, suggesting that vaccination early in the third trimester may be more effective than later in pregnancy.
CONCLUSION
Tdap maternal vaccination results in significantly higher anti-PT IgG in newborn infants and supports the current recommendation of the Brazilian Immunization Program.
Identifiants
pubmed: 31153689
pii: S0264-410X(19)30567-5
doi: 10.1016/j.vaccine.2019.04.079
pmc: PMC7419216
mid: NIHMS1603741
pii:
doi:
Substances chimiques
Antibodies, Bacterial
0
Immunoglobulin G
0
Pertussis Toxin
EC 2.4.2.31
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
5474-5480Subventions
Organisme : Intramural CDC HHS
ID : CC999999
Pays : United States
Informations de copyright
Copyright © 2019 Elsevier Ltd. All rights reserved.
Références
JAMA. 2018 Oct 9;320(14):1464-1470
pubmed: 30304426
Clin Infect Dis. 2017 Nov 29;65(12):1977-1983
pubmed: 29028938
Arch Dis Child Fetal Neonatal Ed. 2017 Sep;102(5):F456-F463
pubmed: 28468899
Clin Vaccine Immunol. 2009 Dec;16(12):1781-8
pubmed: 19864485
Clin Diagn Lab Immunol. 2004 Nov;11(6):1045-53
pubmed: 15539504
Vaccine. 2018 Jun 22;36(27):3984-3991
pubmed: 29789240
Vaccine. 2014 Oct 7;32(44):5787-93
pubmed: 25173476
Pediatr Infect Dis J. 2013 Jun;32(6):695-8
pubmed: 23429559
J Infect Dis. 2014 Aug 15;210(4):604-10
pubmed: 24526741
Vaccine. 1998 Dec;16(20):1907-16
pubmed: 9796042
JAMA. 2014 May 7;311(17):1760-9
pubmed: 24794369
J Comp Pathol. 2007 Jul;137 Suppl 1:S16-9
pubmed: 17553516
Vaccine. 2013 Aug 28;31(38):4172-6
pubmed: 23845808
Vaccine. 2013 Jan 11;31(4):618-25
pubmed: 23200883
Am J Prev Med. 2018 Aug;55(2):159-166
pubmed: 29910115
Vaccine. 2016 Jul 19;34(33):3719-22
pubmed: 27265448
Clin Infect Dis. 2016 Jul 1;63(1):143-4
pubmed: 27090990
Pediatrics. 2015 Oct;136(4):635-41
pubmed: 26347437
Clin Obstet Gynecol. 2008 Sep;51(3):486-97
pubmed: 18677141
Vaccine. 2017 Aug 16;35(35 Pt A):4453-4456
pubmed: 28359620
Expert Rev Anti Infect Ther. 2014 Oct;12(10):1265-75
pubmed: 25139010
Clin Vaccine Immunol. 2012 Jan;19(1):64-72
pubmed: 22116688
Curr Opin Infect Dis. 2017 Jun;30(3):268-273
pubmed: 28362650
BMC Infect Dis. 2015 Oct 23;15:442
pubmed: 26498058
Wkly Epidemiol Rec. 2015 Aug 28;90(35):433-58
pubmed: 26320265
Am J Obstet Gynecol. 2011 Apr;204(4):334.e1-5
pubmed: 21272845
J Infect Dis. 2000 Mar;181(3):1010-3
pubmed: 10720524
J Pediatric Infect Dis Soc. 2018 Feb 19;7(1):11-17
pubmed: 28040688
Clin Infect Dis. 2016 Apr 1;62(7):829-836
pubmed: 26797213
Obstet Gynecol. 2018 Feb;131(2):364-369
pubmed: 29324612
MMWR Morb Mortal Wkly Rep. 2013 Feb 22;62(7):131-5
pubmed: 23425962
BMC Infect Dis. 2018 Mar 13;18(1):126
pubmed: 29534683
Am J Obstet Gynecol. 2016 Aug;215(2):237.e1-6
pubmed: 26968625
Toxins (Basel). 2017 Sep 11;9(9):
pubmed: 28892012